Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations

Rhea-AI Summary

Ocular Therapeutix (NASDAQ: OCUL) will present detailed SOL-1 Phase 3 superiority trial data for AXPAXLI (OTX-TKI) in wet AMD at the 49th Macula Society Annual Meeting on Feb 27, 2026, with presentations starting at 1:00 PM PT (4:00 PM ET).

The company will furnish symposium slides on Form 8-K at 4:00 PM ET on Feb 27 and host an investor webcast to discuss the data on Mar 2, 2026 at 7:30 AM ET; slides and a replay will be available on the company website.

News Market Reaction – OCUL

+8.10%

26 alerts

+8.10% Session close to close

+10.4% Peak in 25 hr 52 min

$1.94B Market Cap

0.7x Rel. Volume

In the Feb 23 session, OCUL gained 8.10%, reflecting a notable positive market reaction. Argus tracked a peak move of +10.4% during that session. Our momentum scanner triggered 26 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +8.1% in the session following this news. A strong positive reaction aligns with inv...

Analysis

The stock moved +8.1% in the session following this news. A strong positive reaction aligns with investors anticipating more clarity on the SOL-1 Phase 3 dataset and AXPAXLI’s positioning. Unlike the earlier selloff on positive topline data, this move followed scheduling and access details for the full presentation and webcast. With shares at $7.78, still well below the 52-week high of $16.44, investors may weigh upcoming detailed data, existing insider selling activity, and potential use of the effective S-3 shelf when assessing durability.

Key Figures

Macula Society Meeting dates: February 25–28, 2026 SOL-1 data session time: February 27, 2026, 1:00 PM PT (4:00 PM ET) SOL-1 symposium window: 12:45–2:15 PM PT +5 more

8 metrics

Macula Society Meeting dates February 25–28, 2026 49th Macula Society Annual Meeting schedule

SOL-1 data session time February 27, 2026, 1:00 PM PT (4:00 PM ET) Start time for SOL-1 data presentations at Macula Society

SOL-1 symposium window 12:45–2:15 PM PT Ocular Therapeutix SOL-1 symposium duration at Macula Society

Investor webcast time March 2, 2026, 7:30 AM ET Conference call and webcast to discuss detailed SOL-1 results

Macula Society meeting number 49th Edition of the Macula Society Annual Meeting

Webcast replay duration At least 30 days Length of time archived webcast will remain available

U.S. dial-in 1-800-579-2543 Participant dial-in number for U.S. investors

International dial-in 1-785-424-1789 Participant dial-in number for international investors

Historical Context

5 past events · Latest: Feb 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 17	Clinical topline results	Positive	-21.3%	Positive SOL-1 Phase 3 superiority data for AXPAXLI in wet AMD with strong endpoints.
Feb 13	Clinical data timing	Positive	-2.0%	Announcement of webcast and timing for forthcoming SOL-1 Phase 3 topline data release.
Feb 06	Inducement equity grants	Neutral	+3.0%	Equity awards to new non-executive employees under inducement plan with defined vesting.
Feb 05	Earnings and pipeline	Negative	+4.2%	Q4 and 2025 results showing revenue decline and large net loss alongside higher R&D spend.
Jan 23	Executive inducement grant	Positive	+6.0%	Sizeable stock option and RSU package granted to new Global Chief Commercial Officer.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows several instances where positive clinical or business updates were followed by negative or muted price reactions, indicating a tendency toward divergence on good news.

Recent Company History

Over the last month, OCUL has focused on its retina franchise and AXPAXLI program. On Feb 5, 2026, it reported 2025 results, highlighting cash of $737.1M and plans for an NDA pending SOL-1. Subsequent releases on Feb 13 and Feb 17 detailed timing and positive topline SOL-1 Phase 3 outcomes. Inducement equity grants on Jan 23 and Feb 6 expanded incentives for new hires and leadership. Today’s announcement fits as a follow-up, scheduling detailed SOL-1 data and investor engagement.

Key Terms

phase 3, wet age-related macular degeneration, wet amd, form 8-k, +2 more

6 terms

phase 3 medical

"SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI)"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

wet age-related macular degeneration medical

"for the treatment of wet age-related macular degeneration (wet AMD)"

A severe eye condition in which abnormal, fragile blood vessels grow beneath the macula — the small central part of the retina responsible for sharp, detailed vision — and leak fluid or blood, causing rapid loss of central sight. Investors care because the condition drives demand for high-cost therapies, medical devices and ongoing care; successful treatments can create sizable markets, affect healthcare spending and influence regulatory and reimbursement decisions, much like fixing a leaking camera lens restores image quality and value.

wet amd medical

"for the treatment of wet age-related macular degeneration (wet AMD)"

Wet AMD (wet age-related macular degeneration) is an eye disease in older adults where abnormal, leaky blood vessels grow under the retina and cause rapid vision loss in the center of the visual field. It matters to investors because it creates a sustained market for treatments, diagnostics and devices: changes in diagnosis rates, new drugs, or reimbursement rules can quickly affect healthcare revenues and the valuation of companies working on therapies.

form 8-k regulatory

"slides will be made available by a Current Report on Form 8-K to be furnished"

A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.

securities and exchange commission regulatory

"to be furnished to the Securities and Exchange Commission (SEC) at 4:00 PM ET"

A national government agency that enforces rules for buying, selling and disclosing information about stocks and other investments, acting like a referee and scorekeeper for financial markets. It requires companies to share clear, regular financial and business information and investigates fraud or rule-breaking, which matters to investors because those rules and disclosures help ensure fair prices, reduce hidden risks and make it easier to compare investment choices.

webcast technical

"The live and archived webcast can also be accessed by visiting the Ocular"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Ocular to present detailed SOL-1 data at the 49th Macula Society Annual Meeting on Friday, February 27, 2026, starting at 1:00 PM PT (4:00 PM ET)

Company to host an investor webcast on Monday, March 2, 2026, at 7:30 AM ET to discuss the Macula Society presentations

BEDFORD, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will present detailed results from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD), at the 49^th Macula Society Annual Meeting on Friday, February 27, 2026, with data presentations starting at 1:00 PM PT (4:00 PM ET). Ocular plans to host an investor webcast on Monday, March 2, 2026, at 7:30 AM ET to discuss the Macula Society presentations.

49^th Macula Society Annual Meeting: February 25 – 28, 2026
San Diego, California

• Symposium Title: Ocular Therapeutix Symposium to Review Detailed SOL-1 Data
  Symposium Date/Time: Friday, February 27, 2026, 12:45 – 2:15 PM PT. Following welcome remarks, SOL-1 data presentations to begin at 1:00 PM PT (4:00 PM ET).
  
  

The SOL-1 Symposium slides will be made available by a Current Report on Form 8-K to be furnished to the Securities and Exchange Commission (SEC) at 4:00 PM ET on Friday, February 27, 2026. Ocular also plans to make a copy of all slides presented at the 49^th Macula Society Annual Meeting available on its website.

SOL-1 Detailed Data Investor Webcast: March 2, 2026
Ocular Therapeutix will host a conference call and webcast to discuss the detailed SOL-1 results being presented at the 49^th Macula Society Annual Meeting. The event will include brief prepared remarks followed by a live Q&A session with Ocular leadership and retina Key Opinion Leaders.

Conference Call and Webcast Information
Date/Time: Monday, March 2, 2026, at 7:30 AM ET
Participant Dial-In (U.S.): 1-800-579-2543
Participant Dial-In (International): 1-785-424-1789
Conference ID: OCULAR
Webcast Access: Please click here

The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be archived for at least 30 days.

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA^®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.

Follow the Company on its website, LinkedIn, or X.

DEXTENZA^® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com

FAQ

When will Ocular Therapeutix (OCUL) present detailed SOL-1 Phase 3 data at the Macula Society meeting?

Ocular Therapeutix will present SOL-1 detailed data on Feb 27, 2026, starting at 1:00 PM PT (4:00 PM ET). According to the company, the symposium runs 12:45–2:15 PM PT with SOL-1 presentations beginning at 1:00 PM PT.

How can investors attend the OCUL investor webcast discussing SOL-1 results on March 2, 2026?

Investors can join the OCUL webcast on Mar 2, 2026 at 7:30 AM ET via the company's investor relations Events and Presentations page. According to the company, the call includes prepared remarks followed by live Q&A with leadership and retina KOLs.

Will Ocular Therapeutix (OCUL) file the SOL-1 symposium slides with the SEC and when?

Yes. Ocular Therapeutix will furnish the SOL-1 symposium slides on Form 8-K at 4:00 PM ET on Feb 27, 2026. According to the company, slides will also be posted on its website after the presentation.

What is AXPAXLI (OTX-TKI) and why is OCUL presenting SOL-1 results at the Macula Society?

AXPAXLI (OTX-TKI) is Ocular's investigational therapy for wet AMD; SOL-1 is a Phase 3 superiority trial. According to the company, presenting detailed SOL-1 data at the Macula Society enables scientific scrutiny and investor briefing on trial findings and implications.

Will the OCUL webcast of the SOL-1 presentation be available after the live event?

Yes. The live webcast will be archived after the event and available for at least 30 days. According to the company, investors can access the replay via the Events and Presentations section of the company's investor relations website.